Osteoporosis Medicines

Leading Wholesale Trader of terifrac teriparatide 750 mcg injection, denosumab solution for injection and calcitonin salmon nasal solution usp from Nagpur.

Terifrac Teriparatide 750 Mcg Injection

Request Callback

₹ 5500 Get Latest Price

Product Brochure
Strength750 mcg
Pack Size3ml
Pack TypeCartridge
BrandTerifrac
ManufacturerIntas Pharmaceuticals Ltd
Usage/ApplicationTo Treat Osteoporosis
Country of OriginMade in India
Teriparatide (Terifrac) is used to treat osteoporosis in men and women who have a high risk of bone fracture. Teriparatide forms new bone, increases bone mineral density and bone strength, and as a result reduces the chance of getting a fracture (broken bone)

Denosumab Solution For Injection

Request Callback

₹ 950 Get Latest Price

Product Brochure
Dose/Strength120 mg
Usage/ApplicationPersonal
Product TypeFinished Product
BrandEsentra 120
CompositionDenosumab Solution For Injection
Country of OriginMade in India
Packaging SizeVial
Packaging TypeBox
Esentra 120mg Injection is a medicine used in the treatment of osteoporosis in postmenopausal women and in men at increased risk of fractures. It makes the bones strong and reduce the risk of fractures.

Calcitonin Salmon Nasal Solution Usp

Request Callback

₹ 1550 Get Latest Price

Product Brochure
Packaging Size3.7ml
Packaging TypeBottle
BrandCalcican Nasal spray
ManufacturerAmerican remedies
Usage/ApplicationTo Treat Osteoporosis
Prescription/Non-PrescriptionPrescription
CompositionCalcitonin Salmon Nasal Solution Usp
Country of OriginMade In India
Calcitonin nasal spray is used together with calcium and vitamin D to treat bone loss in women with postmenopausal osteoporosis who have been postmenopause for at least 5 years. This medicine is available only with your doctor's prescription. This product is available in the following dosage forms: Spray
X

Contact Us

Aaryan (CEO)
Derma Medical LLP
Plot No. 19/1, 1st Floor,Diamond, One Appts Dhantoli,Nagpur, Nagpur - 440012, Maharashtra, India

Get Directions
Send Email
Share: